

# Yitian Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8648943/publications.pdf>

Version: 2024-02-01

32  
papers

957  
citations

623188

14  
h-index

552369

26  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. <i>Pharmacological Reports</i> , 2022, 74, 47-66.	1.5	7
2	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. <i>Human Genetics</i> , 2022, 141, 1113-1136.	1.8	17
3	Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma. <i>Genetics in Medicine</i> , 2022, 24, 157-169.	1.1	0
4	Computational Methods and Approaches in Pharmacogenomic Research. , 2022, , 53-83.		1
5	Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives. <i>Pharmacological Reviews</i> , 2022, 74, 141-206.	7.1	23
6	Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics. <i>Pharmacological Research</i> , 2022, 176, 106087.	3.1	9
7	Pharmacogenomics of Antihypertensive Drugs in Brazil: Recent Progress and Clinical Implications. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1263-1275.	0.6	1
8	Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia. <i>Pharmaceutics</i> , 2022, 14, 944.	2.0	4
9	Genome-wide association meta-analysis identifies 48 risk variants and highlights the role of the stria vascularis in hearing loss. <i>American Journal of Human Genetics</i> , 2022, 109, 1077-1091.	2.6	27
10	Global Frequencies of Clinically Important <i>HLA</i> Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 160-174.	2.3	35
11	Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1095-1111.	0.8	8
12	Pharmacogenomics in the era of next generation sequencing – from byte to bedside. <i>Drug Metabolism Reviews</i> , 2021, 53, 253-278.	1.5	19
13	Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 626-636.	2.3	16
14	Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation. <i>Frontiers in Genetics</i> , 2021, 12, 736626.	1.1	1
15	Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 735-755.	1.6	3
16	Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. <i>Science Advances</i> , 2021, 7, eabi6856.	4.7	16
17	Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 52-58.	1.9	3
18	Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. <i>British Journal of Cancer</i> , 2020, 123, 1782-1789.	2.9	23

#	ARTICLE	IF	CITATIONS
19	Impact of variants in ATP-binding cassette transporters on breast cancer treatment. <i>Pharmacogenomics</i> , 2020, 21, 1299-1310.	0.6	9
20	Ethnogeographic and inter-individual variability of human ABC transporters. <i>Human Genetics</i> , 2020, 139, 623-646.	1.8	34
21	Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 2475-2487.	2.3	20
22	In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na <sup>+</sup> -Taurocholate Cotransporting Polypeptide (NTCP). <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 150-167.	1.5	17
23	CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. <i>Pharmacogenomics</i> , 2019, 20, 1085-1092.	0.6	2
24	Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2019, 10, 1093.	1.6	62
25	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. <i>Pharmacogenomics</i> , 2019, 20, 122-152.		83
26	An optimized prediction framework to assess the functional impact of pharmacogenetic variants. <i>Pharmacogenomics Journal</i> , 2019, 19, 115-126.	0.9	109
27	Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. <i>Toxicological Sciences</i> , 2018, 163, 655-665.	1.4	140
28	Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data. <i>Frontiers in Pharmacology</i> , 2018, 9, 1437.	1.6	62
29	Integrating rare genetic variants into pharmacogenetic drug response predictions. <i>Human Genomics</i> , 2018, 12, 26.	1.4	166
30	Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. <i>Journal of Medical Genetics</i> , 2018, 55, 617-627.	1.5	24
31	Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. <i>Journal of Lipid Research</i> , 2018, 59, 1987-2000.	2.0	19
32	Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-9-16.	0.0	0